In this report, we cover catalysts from 23 drugs, categorized into approval and data readouts, as well as deals expected to occur in Q3 2025. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Norstella’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

The results of the catalysts highlighted in our Q2 2025 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q3 2025. The catalyst list is also provided in Excel by downloading the supplemental material at the top of this page. Like our report? Have any questions or feedback?

Please let us know at askanalyst@sagientresearch.com.